 "dr reddy's laboratory , dr reddy , drl pharma sector")
Dr Reddy's Laboratories Ltd on Tuesday said the US health regulator has issued a Form 483 with seven observations to its active pharmaceutical ingredient manufacturing facility in Bollaram, Hyderabad.
"The US Food & Drug Administration (USFDA) today completed a GMP inspection at our API manufacturing facility (CTO-2) in Bollaram, Hyderabad," Dr Reddy's Laboratories Ltd (DRL) said in a regulatory filing.
The inspection was conducted from November 13-19, 2024, it added.
"We have been issued a Form 483 with seven observations, which we will address within the stipulated timeline," the company said.
As per US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
 "Flipkart")
 "Chamarajanagar plant, KM Birla")
 "IHCL Taj hotel brand")
 "Adani Enterprises, Adani group")
 "Oil india")
